Inventors: V Vamsi Krishna Venuganti

The study investigates the use of lipid nanoparticles (LNPs) to deliver survivin mRNA antigens and CTLA-4 inhibitors specifically to lymph nodes for targeted oral cancer immunotherapy. Survivin mRNA, a tumor-associated antigen, aims to stimulate an immune response against cancer cells, while CTLA-4 inhibitors are designed to enhance the immune system's.